Tag: Food and Drug Administration (FDA)

Displaying 1 - 20 of 24 results.

Pages

Filtering by content type: Press Release

The Federal Trade Commission is sending 51,875 payments totaling more than $59 million to consumers who were victims of an allegedly deceptive scheme by Reckitt Benckiser Group and
The Federal Trade Commission is sending 70,142 checks and PayPal payments totaling $3,864,824 to consumers nationwide who bought Quell, a wearable device that supposedly would treat chronic pain throughout the body when placed below the knee.
Indivior, Inc. has agreed to pay $10 million to settle Federal Trade Commission charges that it violated antitrust laws through a deceptive scheme to thwart lower priced generic competition with its branded opioid replacement therapy drug Suboxone. The proposed stipulated order for a permanent...
The Federal Trade Commission and U.S. Food and Drug Administration (FDA) have sent warning letters to seven companies allegedly selling unapproved products that may violate federal law by making deceptive or scientifically unsupported claims about their ability to treat coronavirus (COVID-19). The...
Under a settlement with the Federal Trade Commission, the marketers of an electrical nerve stimulation device called Quell have agreed to pay at least $4 million and stop making deceptive claims that the device treats pain throughout the body when placed below the knee and is clinically proven and...
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the FDA’s White Oak Campus in Silver Spring, Maryland and will also be webcast.
Federal Trade Commission Chairman Joseph J. Simons today joined Food and Drug Administration Commissioner Stephen Hahn in signing a joint statement promoting competition in biologics markets.
The Federal Trade Commission announced a joint warning letter issued with the U.S. Food and Drug Administration (FDA) to Rooted Apothecary, LLC for selling products containing cannabidiol (CBD) online with potentially unsubstantiated claims that the products can treat autism, attention-deficit/...
Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic competition to its branded drug Suboxone. Suboxone is a prescription oral medication used to minimize...
The agencies sent the letters to firms that manufacture and market flavored e-liquid products. They cite postings by influencers on social media sites such as Facebook, Instagram, and Twitter that endorse the target companies’ products, without any warnings that the products contain nicotine, an...
The Federal Trade Commission staff has responded to the Food and Drug Administration’s request for comment on its updated industry guidance regarding nonproprietary naming of biological products.The FDA proposes to add a unique, meaningless suffix to the nonproprietary name of all biosimilar and...
As part of its ongoing efforts to ensure that dietary supplements and other health-related products are advertised truthfully, and that efficacy claims made for such products are supported by competent and reliable scientific evidence, the Federal Trade Commission joined the U.S. Food and Drug...
As part of its ongoing efforts to ensure that dietary supplements and other health-related products are advertised truthfully, and that efficacy claims made for such products are supported by competent and reliable scientific evidence, the Federal Trade Commission has joined the U.S. Food and Drug...
The Federal Trade Commission has responded to the Food and Drug Administration’s request for comment on its revised draft guidance, which aims to deter pharmaceutical companies from abusing the citizen petition process to delay approval of and competition from generic drugs.
The Federal Trade Commission responded to the U.S. Department of Health and Human Services’ request for comment to its publication, Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. The publication seeks to “increase competition and end the gaming of regulatory processes that may keep...
The Federal Trade Commission has filed an amicus brief in Takeda Pharmaceutical Co. v Zydus Pharmaceuticals (USA) Inc., which is a patent infringement case pending before the U.S. District Court for the District of New Jersey.
As part of ongoing efforts to protect youth from the dangers of nicotine and tobacco products, today the Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) jointly issued 13 warning letters to manufacturers, distributors, and retailers for selling e-liquids used in e-...
The Federal Trade Commission (FTC) and U.S. Food and Drug Administration (FDA) will host a joint media call-in on Tuesday, May 1, 2018 at 11 a.m. to discuss actions regarding youth-related tobacco issues. Media in the United States or Canada may call 877-918-2507. International callers will need...
The Federal Trade Commission and the U.S. Food and Drug Administration (FDA) today posted warning letters to 11 marketers and distributors of opioid cessation products for illegally marketing products with unproven claims about their ability to help in the treatment of opioid addiction and...
In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to stop anticompetitive conduct in the pharmaceutical industry.

Pages